1. Home
  2. EKSO vs MDAI Comparison

EKSO vs MDAI Comparison

Compare EKSO & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ekso Bionics Holdings Inc.

EKSO

Ekso Bionics Holdings Inc.

HOLD

Current Price

$10.01

Market Cap

37.9M

Sector

Health Care

ML Signal

HOLD

MDAI

Spectral AI Inc.

HOLD

Current Price

$1.47

Market Cap

39.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EKSO
MDAI
Founded
2005
2013
Country
United States
United States
Employees
N/A
78
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
39.6M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
EKSO
MDAI
Price
$10.01
$1.47
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$9.50
$3.25
AVG Volume (30 Days)
70.0K
677.7K
Earning Date
05-04-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
41.76
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$81.23
N/A
Revenue Next Year
$7.29
$63.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$1.05
52 Week High
$13.50
$3.21

Technical Indicators

Market Signals
Indicator
EKSO
MDAI
Relative Strength Index (RSI) 43.96 50.13
Support Level $9.64 $1.25
Resistance Level $10.76 $1.48
Average True Range (ATR) 0.90 0.15
MACD -0.18 0.02
Stochastic Oscillator 0.00 48.42

Price Performance

Historical Comparison
EKSO
MDAI

About EKSO Ekso Bionics Holdings Inc.

Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.

About MDAI Spectral AI Inc.

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.

Share on Social Networks: